metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Tratamiento quirúrgico tras quimioterapia neoadyuvante en el cáncer de mama op...
Información de la revista
Vol. 74. Núm. 6.
Páginas 325-329 (diciembre 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 74. Núm. 6.
Páginas 325-329 (diciembre 2003)
Acceso a texto completo
Tratamiento quirúrgico tras quimioterapia neoadyuvante en el cáncer de mama operable: once años de experiencia
Surgical treatment after neoadjuvant chemotherapy in operable breast cancer: An eleven-year experience
Visitas
5938
Vicente Plaa,1
Autor para correspondencia
vplamarti@yahoo.es

Correspondencia: Dr. V. Pla. Avda. Primado Reig, 1895 A. 46020 Valencia. España.
, Elvira Bucha, Manuel Muñoza, Cristina Fernándeza, María José Safonta, Antonio Galána, Vicente Ginera, José Vicente Roigb
a Servicio de Oncología Médica. Hospital de Sagunto. Sagunto.
b Servicio de Cirugía General y del Aparato Digestivo. Hospital de Sagunto. Sagunto. España.
Este artículo ha recibido
Información del artículo
Resumen
Introducción

El objetivo del estudio ha sido evaluar el tratamiento conservador tras la quimioterapia de inducción y analizar los resultados obtenidos tras 11 años de experiencia con la neoadyuvancia en el cáncer de mama.

Pacientes y método

Se administró quimioterapia de inducción a las pacientes con cáncer de mama no metastásico con tumores mayores de 3 cm. Se indicó tratamiento conservador en las pacientes con un tamaño tumoral ??3 cm y en las que no existieran contraindicaciones.

Resultados

Entre enero de 1990 y diciembre del 2000 se administró quimioterapia de inducción a 146 pacientes. El tamaño tumoral medio fue de 5,14 cm, que pasó a ser de 2,8 cm tras la inducción (p < 0,05). La respuesta a la quimioterapia fue completa en el 10% de las pacientes y parcial en el 75%; el 15% restante no respondió. Se realizó tratamiento quirúrgico conservador en el 31% de los casos (el 55% de los que estaban en estadio IIa, el 31% de los de estadio IIb, el 19% de los de estadio IIIa y el 3% de los de estadio IIIb). En los tumores menores de 5 cm sin afección ganglionar fue más factible el tratamiento conservador (p < 0,05). Tras un seguimiento medio de 44,4 meses, 34 pacientes (23%) desarrollaron metástasis y 4 (2,7%) recurrencia local. Las pacientes con tumores mayores de 5 cm y afección axilar tras la quimioterapia presentaron enfermedad metastásica con más frecuencia (p < 0,05).

Conclusión

La quimioterapia preoperatoria reduce significativamente el tamaño tumoral y permite el tratamiento quirúrgico conservador con un riesgo bajo de recidiva local. La afección axilar y el tamaño tumoral ral tras la inducción son importantes factores de pronóstico.

Palabras clave:
Carcinoma de mama
Quimioterapia neoadyuvante
Tratamiento conservador
Factores de pronóstico
Introduction

The aim of this study was to evaluate conservative treatment after induction chemotherapy and to analyze the results obtained after 11 years’ experience with neoadjuvant therapy in breast cancer.

Patients and method

Induction chemotherapy was administered to patients with non-metastatic breast cancer and tumors of more than 3 cm. Conservative treatment was indicated in patients with a tumoral size less than or equal to 3 cm and without contraindications.

Results

Between January 1990 and December 2000, induction therapy was administered to 146 patients. The mean tumoral size was 5.14 cm and was 2.8 cm after induction (p < 0.05). Response to chemotherapy was complete in 10% of the patients and partial in 75%. No response was obtained in 15%. Conservative surgical treatment was performed in 31% of the patients (55% of those with IIa, 31% of those with IIb, 19% of those with IIIa and 3% of those with IIIb). In tumors of less than 5 cm without lymph node involvement, conservative treatment was more feasible (p < 0.05). After a mean follow-up of 44.4 months, 34 patients (23%) developed metastases and 4 (2.7%) had local recurrence. Patients with tumors or more than 5 cm and axillary involvement after chemotherapy more frequently presented metastases (p < 0.05).

Conclusion

Preoperative chemotherapy significantly reduces tumoral size, allowing conservative surgical treatment with a low risk of local recurrence. Axillary involvement and tumoral size after induction are important prognostic factors.

Key words:
Breast carcinoma
Neoadjuvant chemotherapy
Conservative treatment
Prognostic factors
El Texto completo está disponible en PDF
Bibliografía
[1.]
U. Veronesi, R. Sacczzi, M. Del Vechio, A. Banfi, C. Clemente, M. De Lena, et al.
Comparing radical mastectomy with quadrantectomy, axilar dissection and radiotherapy in patients with small cancers of the breast.
N Engl J Med, 305 (1981), pp. 6-11
[2.]
B. Fisher, M. Bauer Margoles, R. Poisson, Y. Pilch, C. Redmond, et al.
Five-years results of a randomized clinical trialcomparing total and segmental mastectomy with or without radiation in the treatment of breast cancer.
N Engl J Med, 312 (1985), pp. 665-673
[3.]
M. De Lena, R. Zucali, G. Viganotti, P. Valagussa, G. Bonadonna, et al.
Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.
Cancer Chemother Pharmacol, 1 (1978), pp. 53-59
[4.]
B. Fisher, A. Brown, E. Mamounas, S. Wieans, A. Robindoux, R.G. Margolese, et al.
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adyuvant Breast and Bowel Project B-18.
J Clin Oncol, 15 (1997), pp. 2483-2493
[5.]
T.J. Powles, T.F. Hickish, A. Makris, S.E. Ashley, M.E. O’Brien, V.A. Tdy, et al.
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
J Clin Oncol, 13 (1995), pp. 547-552
[6.]
J.D. Cunningham, S.E. Weiss, S. Ahmed, J.M. Bratton, I.J. Bleiweis, P.I. Tartter, et al.
The efficacy of neoadyuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer.
Cancer Invest, 16 (1998), pp. 80-86
[7.]
L. Mauriac, G. McGrogan, A. Avril, M. Durand, A. Floquet, M. Debled, et al.
Neoadyuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicenter randomized trial with 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS.
Ann Oncol, 10 (1999), pp. 47-52
[8.]
M.S. O’Reilly, T. Boehm, Y. Shing, N. Fukani, G. Vasios, W.S. Lane, et al.
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
Cell, 88 (1997), pp. 277-285
[9.]
N. Gunduz, B. Fisher, E.A. Saffer.
Effect of surgical removal on growth and kinetics of residual tumor.
Cancer Res, 39 (1979), pp. 3861-3865
[10.]
D.C. Abraham, R.C. Jones, S.E. Jones, J.H. Cheek, G.N. Peters, S.M. Knox, et al.
Evaluation of neoadyuvant chemetherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
[11.]
L. Esserman, N. Hylton, L. Yassa, J. Barclay, S. Frankel, E. Sickles.
Utility of magnetic resonance imaging in the management of breast cancer: evidence of improved preoperative staging.
J Clin Oncol, 17 (1999), pp. 110-119
[12.]
H.M. Kuerer, L.A. Newman, A.U. Buzdar, K.K. Hunt, K. Dhingra, T.A. Buchholz, et al.
Residual metastatic axillary lymph nodes following neoadyuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Am J Surg, 176 (1998), pp. 502-509
[13.]
H.M. Kuerer, L.A. Newman, A.U. Buzdar, K. Dhingra, T.A. Buchholz, K.K. Hunt, et al.
Pathologic tumor response in the breast following neoadyuvant chemotherapy predicts axillary lymph node status.
Cancer J Sci Am, 4 (1998), pp. 230-236
[14.]
G. Bonadona, P. Valagussa, C. Brambilla, L. Ferrari, A. Molitenni, M. Terenziani, et al.
Primary chemotherapy in operable breast cancer: eight year experience at the Milan Cancer Institute.
J Clin Oncol, 16 (1998), pp. 93-100
[15.]
Y. Remvikos, M. Jouve, P. Beuzevok, P. Viehl, H. Magdelenat, P. Pouillart.
Cell cycle modifications of breast cancers during neoadyuvant chemotherapy: a flow cytometry study on fine needle aspirates.
Eur J Cancer, 13 (1993), pp. 1843-1848
[16.]
P.C. Willsher, S.E. Pinder, J.M. Gee, I.O. Ellis, S.Y. Chan, R.I. Nicholson, et al.
C-erb B2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer.
Anticancer Res, 18 (1998), pp. 3695-3698
[17.]
J. Chang, T.J. Powles, D.C. Allred, S.E. Ashley, G.M. Clark, A. Makris, et al.
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
J Clin Oncol, 17 (1999), pp. 3058-3063
[18.]
G. Vlastos, N.Q. Mirza, J.T. Lenert, K.K. Hunt, F.C. Ames, B.W. Feig, et al.
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Cancer, 88 (2000), pp. 1417-1424
[19.]
G. Calais, C. Berger, P. Descamps, S. Chapet, A. Reynaud-Bougnoux, G. Body, et al.
Conservative treatment feasibility with induction chenotherapy, surgery, and radioterapy for patients with breast carcinoma larger than 3 cm.
Cancer, 74 (1994), pp. 1283-1288
[20.]
U. Veronesi, G. Bonadona, E. Zurrida, V. Galimberti, M. Greco, C. Brambilla, et al.
Conservation surgery after primary chemotherapy in large carcinomas of the breast.
Ann Surg, 222 (1995), pp. 612-618
[21.]
B. Fisher, J. Bryant, N. Wolmark, E. Mamounas, A. Brown, E.R. Fisher, et al.
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
J Clin Oncol, 16 (1998), pp. 2672-2685
[22.]
A. Makris, T.J. Powles, S.E. Ashley, J. Chang, T. Hickish, V.A. Tidy, et al.
A reduction in the requirements for mastectomy in a randomized trial of neoadyuvant chemotherapy in primary breast cancer.
Ann Oncol, 9 (1998), pp. 1179-1184
[23.]
P. Ellis, I. Smith, S.E. Ashley, G. Walsh, S. Ebbs, M. Baum, et al.
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
J Clin Oncol, 16 (1998), pp. 107-114
[24.]
E. Brain, C. Garrino, J.L. Misset, I.G. Carbonero, M. Itzhaki, E. Cvitkovitz, et al.
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracicline-based neoadyuvant chemotherapy.
Br J Cancer, 75 (1997), pp. 1360-1367
[25.]
H.M. Kuerer, A.A. Sahin, K.K. Hunt, L.A. Newman, T.M. Breslin, F.C. Ames, et al.
Incidence and impact of documented eradication of breast cancer axilary limph node metastases before surgery in patients treated with neoadyuvant chemotherapy.
Ann Surg, 230 (1999), pp. 72-78
[26.]
D.R. Mc Cready, G.N. Hortobagyi, S.W. Kau.
The prognostic significance of limph node metastases after preoperative chemotherapy for locally advanced breast cancer.
Arch Surg, 124 (1989), pp. 21-25
[27.]
P. Valagussa, M. Zambetti, G. Bonadona, R. Zucali, G. Mezzanotte, U. Veronesi.
Prognostic factors in locally advanced noninflamatory breast cancer. Long-term results following primary chemotherapy.
Breast Cancer Res Treat, 15 (1990), pp. 137-147
[28.]
J.J. Stebbing, A. Gaya.
The evidence-based use of induction chemotherapy in breast cancer.
Breast Cancer, 8 (2001), pp. 23-27
[29.]
T.M. Breslin, L. Cohen, A. Sahin, J.B. Fleming, H.M. Kuerer, E.S. Delpassand, et al.
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
J Clin Oncol, 18 (2000), pp. 3480-3486
[30.]
L.F. Cohen, T.M. Bresling, H.M. Kuerer, M.I. Ross, K.K. Hunt, A.A. Sahin.
Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadyuvant chemotherapy.
Am J Surg Pathol, 24 (2000), pp. 1226-1272
[31.]
K.S. Nason, B.O. Anderson, D.R. Byrd, L.K. Dunnwald, J.F. Eary, R. Mankoff, et al.
Increase false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.
Cancer, 89 (2000), pp. 2187-2194
Copyright © 2003. Asociación Española de Cirujanos
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos